

**Appendix J**

**UnitedHealth Group and Amedisys Redaction Log OHA Request for Information**

Redaction	Document	Page and Paragraph Number	Information Redacted	Reason for Redaction	Statutory Basis
<b>Preliminary Review Documents</b>					
1	Appendix A	pg. 2, ¶12	UHG personnel and responsibilities	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
2	Appendix A	pg. 2, ¶14	LHC patient counts and clinical staff counts in Oregon	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
3	Appendix A	pg. 2, ¶15	The number of Refresh unique patient counts and number of employees in Oregon	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
4	Appendix A	pg. 2, ¶16	The number of Optum Pharmacies unique patient counts and number of employees in Oregon	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
5	Appendix A	pg. 3, ¶11	The number of Optum Care unique patient counts and number of employees in Oregon	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
6	Appendix A	pg. 3, ¶12	The number of Optum Health Services for I-SNP/IE-SNPs unique patient counts and number of employees in Oregon	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
7	Appendix A	pg. 3, ¶13	The number of SCA unique patient counts and number of employees in Oregon	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
8	Appendix A	pg. 3, ¶14	The number of Landmark unique patient counts and number of employees in Oregon	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
9	Appendix A	pg. 3, ¶15	The number of HouseCalls unique patient counts and number of employees in Oregon	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
10	Appendix A	pg. 4, ¶11	The number of AbleTo unique patient counts and number of employees in Oregon	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
11	Appendix A	pg. 4, ¶16	The number of Amedisys unique patient counts and number of employees in Oregon	Non-public information that pertains to Amedisys strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
12	Appendix C	pg. 1, ¶¶12-4	UHG and Amedisys geographic coverage, staffing, and patient capacity for Optum and Amedisys locations in Oregon	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets

**Appendix J**

**UnitedHealth Group and Amedisys Redaction Log OHA Request for Information**

13	Appendix C	pg. 2, ¶¶1-5	UHG and Amedisys geographic coverage, staffing, and patient capacity for Optum and Amedisys locations in Oregon	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
14	Appendix C	pg. 3, ¶¶1, 3-6	UHG and Amedisys geographic coverage, staffing, and patient capacity for Optum and Amedisys locations in Oregon	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
15	Appendix C	pg. 4, ¶1	UHG and Amedisys geographic coverage, staffing, and patient capacity for Optum and Amedisys locations in Oregon	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
16	Optum Oregon Entities - Individual NPIs (Partial Submission of 12-19-2023)	Entire Document	Competitively sensitive non-public information regarding the number of providers and the mix of specialties of providers by individual service line.	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
17	2024.01.02 Email (Partial submission of 1-2-2024)	Purchase price information for UHG deals in Oregon	Competitively sensitive non-public information regarding the valuation UHG assigns to certain assets and the prices UHG has agreed to pay for those assets.	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
18	2024.01.02 Email (Partial submission of 1-2-2024)	UHG deals that have been pursued but not completed	Competitively sensitive non-public information regarding targets that UHG has considered.	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
19	AbleTo Individual Provider NPIs (Partial submission of 1-2-2024)	Entire Document	Competitively sensitive non-public information regarding the number of providers and the mix of specialties of providers by individual service line.	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
20	UHG and Amedisys Org Chart (Partial submission of 1-5-2024)	Entire Document	Competitively sensitive non-public information regarding the structuring of UHG subsidiaries	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets

**Appendix J**

**UnitedHealth Group and Amedisys Redaction Log OHA Request for Information**

21	Landmark and HouseCalls NPIs (Partial submission of 1-5-2024)	Entire Document	Competitively sensitive non-public information regarding the number of providers and the mix of specialties of providers by individual service line.	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
22	Amedisys Unique Patients Served (Partial submission of 1-5-2024)	Entire Document	Competitively sensitive non-public information pertaining to Amedisys service line capabilities.	Non-public information that pertains to Amedisys and could be used for business advantage	ORS 192.345(2) Trade secrets
23	Attachment 1 - M&A Lists (Partial submission of 1-31-2024)	All documents in folder	Competitively sensitive non-public information regarding targets that UHG and LHC considered, their business strategy, and valuations.	Non-public information that pertains to UHG'S strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
24	Attachment 2 - Pipeline Reports (Partial submission of 2-2-2024)	All documents in folder	Competitively sensitive non-public information regarding targets that UHG and LHC considered, their negotiation tactics, and valuations.	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
25	Attachment 3 - Individual provider NPIs for OptumCare, Refresh, HouseCalls, I/E-SNP, Landmark, and AbleTo (Partial submission of 2-2-2024)	All documents in folder	Competitively sensitive non-public information regarding the number of providers and the mix of specialties of providers by individual service line.	Non-public information that pertains to Amedisys and UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
26	Appendix F-CONFIDENTIAL (Partial submission of 2-2-2024)	Item 3(b)	Competitively sensitive non-public information regarding acquisition target that UHG considered but did not complete	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
27	Appendix F-CONFIDENTIAL (Partial submission of 2-2-2024)	Item 4 chart	Competitively sensitive non-public information regarding the number of unique members in Oregon by plan type.	Non-public information that pertains to UHG strategy and could be used for business advantage	ORS 192.345(2) Trade secrets
<b>Comprehensive Review Documents</b>					
1	Appendix A	All documents in folder		Contains competitively sensitive non-public information regarding UHG's submission to submit a bid for Amedisys.	ORS 192.345(2) Trade secrets.
2	Appendix A	Project Aurora Delegation Authority Pg. 9-16	Legally privileged information.	The redacted information contains legally privileged information.	Attorney-client privilege.
3	Appendix B	Entire document		Contains competitively sensitive non-public information regarding UHG's advisors and consultants.	ORS 192.345(2) Trade secrets.

**Appendix J**

**UnitedHealth Group and Amedisys Redaction Log OHA Request for Information**

4	Appendix C	All documents in folder		Contains competitively sensitive non-public information regarding UHG's budgets, quarterly reports, and annual reports.	ORS 192.345(2) Trade secrets.
5	Appendix D	All documents in folder		Contains competitively sensitive non-public information regarding UHG's advisors and consultants pro forma projections.	ORS 192.345(2) Trade secrets.
6	Appendix E	Entire document		Contains list of non-public investigations.	ORS 192.345(2) Trade secrets.
7	Appendix F	All documents in folder		Contains UHG's non-public and competitively sensitive plans for divestiture.	ORS 192.345(2) Trade secrets.
8	Appendix G	Entire document		List of competitively sensitive non-public information regarding names and addresses of SNF residents who have received services from OHSI since 2019.	ORS 192.345(2) Trade secrets.
9	Appendix I	Entire Workbook		Confidential non-public information regarding Amedisys' payment history, patient volumes and demographics, and staffing.	ORS 192.345(2) Trade secrets.
10	United Response re UHG-Amedisys Requests	Pg. 31, item 5	Confidential information pertaining to Amedisys' budget.	Competitively sensitive non-public information regarding Amedisys' budget.	ORS 192.345(2) Trade secrets.
11	United Response re UHG-Amedisys Requests	Pg. 32, item 8	Confidential information pertaining to UHG divestiture plans.	Competitively sensitive non-public information regarding UHG divestiture plans.	ORS 192.345(2) Trade secrets.
12	United Response re UHG-Amedisys Requests	Pg. 36, item 16	Confidential information pertaining to UHG's rationale for the transaction.	Competitively sensitive non-public information regarding UHG deal rationale.	ORS 192.345(2) Trade secrets.
13	United Response re UHG-Amedisys Requests	Pg. 37, item 17	Information pertaining to confidential documents used to respond to item 16.	Competitively sensitive non-public information regarding UHG deal rationale.	ORS 192.345(2) Trade secrets.
14	United Response re UHG-Amedisys Requests	Pg. 53, item 22	Non-public information regarding LHC and Amedisys' capacity to serve patients in 2023.	Competitively sensitive non-public information regarding capacity.	ORS 192.345(2) Trade secrets.